Cargando…
Chemokine Receptor-Specific Antibodies in Cancer Immunotherapy: Achievements and Challenges
The 1990s brought a burst of information regarding the structure, expression pattern, and role in leukocyte migration and adhesion of chemokines and their receptors. At that time, the FDA approved the first therapeutic antibodies for cancer treatment. A few years later, it was reported that the chem...
Autores principales: | Vela, Maria, Aris, Mariana, Llorente, Mercedes, Garcia-Sanz, Jose A., Kremer, Leonor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4311683/ https://www.ncbi.nlm.nih.gov/pubmed/25688243 http://dx.doi.org/10.3389/fimmu.2015.00012 |
Ejemplares similares
-
Chemokines and Chemokine Receptors: New Targets for Cancer Immunotherapy
por: Mollica Poeta, Valeria, et al.
Publicado: (2019) -
Editorial: Is the Recent Burst of Therapeutic Anti-tumor Antibodies the Tip of an Iceberg?
por: Kremer, Leonor, et al.
Publicado: (2018) -
Will a mAb-Based Immunotherapy Directed against Cancer Stem Cells Be Feasible?
por: Santamaria, Silvia, et al.
Publicado: (2017) -
Immunomodulatory Monoclonal Antibodies in Combined Immunotherapy Trials for Cutaneous Melanoma
por: Aris, Mariana, et al.
Publicado: (2017) -
92R Monoclonal Antibody Inhibits Human CCR9(+) Leukemia Cells Growth in NSG Mice Xenografts
por: Somovilla-Crespo, Beatriz, et al.
Publicado: (2018)